Immuno-Oncology Co-Culture Models Market Global Report 2026

The immuno-oncology co-culture models market size has grown rapidly in recent years. It will grow from $0.93 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 14.0%. The growth during the historic period can be attributed to growing investment in cancer research, increasing adoption of in vitro disease models, rising focus on immunotherapy development, expanding demand for predictive preclinical testing, and higher use of advanced cell culture technologies.

The immuno-oncology co-culture models market size is expected to see rapid growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 13.6%. The growth during the forecast period can be attributed to increasing demand for personalized immuno-oncology research, rising adoption of patient-derived tumor models, growing investment in next-generation preclinical platforms, expanding use of organoid and microfluidic technologies, and greater focus on precision cancer therapeutics. Major trends in the forecast period include growing adoption of three-dimensional tumor microenvironment models, increasing use of patient-derived co-culture systems, rising demand for predictive immunotherapy screening platforms, expansion of advanced tumor-immune interaction studies, and greater focus on physiologically relevant in vitro cancer models.

The rising burden of cancer is expected to drive the growth of the immuno-oncology co-culture models market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The cancer burden is increasing due to greater exposure to risk factors, including aging populations and lifestyle changes, which contribute to a higher incidence of new cancer cases worldwide. Immuno-oncology co-culture models help address the growing cancer burden by enabling more accurate simulation of interactions between tumors and immune cells, thereby improving drug discovery and accelerating the development of targeted cancer therapies. For instance, in October 2025, according to the Australian Government, an Australia-based government department, approximately 169,759 cancer cases were diagnosed, along with around 53,545 cancer-related deaths. Therefore, the rising burden of cancer is driving the growth of the immuno-oncology co-culture models market.

Major companies operating in the immuno-oncology co-culture models market are focusing on developing advanced open organ-on-chip platforms to support physiologically relevant tumor microenvironment modeling, improve studies of immune cell and cancer cell interactions, and accelerate preclinical drug discovery. Open organ-on-chip platforms are modular microphysiological systems that enable researchers to construct and customize complex multicellular co-culture models for investigating immune responses and evaluating immunotherapies. For instance, in June 2024, Dynamic42 GmbH, a Germany-based organ-on-chip technology company, launched the DynamicOrgan System, an open organ-on-chip platform for organ model development. The platform allows researchers to develop customizable immunocompetent organ and tumor models by integrating immune cells, vascular components, and three-dimensional tissues. It supports the development of immuno-oncology co-culture models for cancer research, disease modeling, and preclinical drug screening while providing improved physiological relevance.

In January 2025, MilliporeSigma, a US-based life science solutions provider, acquired HUB Organoids Holding B.V. for an undisclosed amount. Through this acquisition, MilliporeSigma aims to broaden access to organoid technology and strengthen its next-generation biology portfolio to support faster and more effective drug development. HUB Organoids Holding B.V. is a Netherlands-based biotechnology company that provides immuno-oncology co-culture model systems.

Major companies operating in the immuno-oncology co-culture models market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Corning Incorporated, Lonza Group, Agilent Technologies Inc., Sartorius AG, Revvity Inc., Bio-Rad Laboratories Inc., Tecan Group AG, Evotec SE, STEMCELL Technologies Inc., Miltenyi Biotec, Sino Biological Inc., Champions Oncology Inc., MIMETAS B.V., Emulate Inc., CN Bio Innovations Limited, InSphero AG, Axol Bioscience Limited, Creative Biolabs Inc., KiYatec Inc., TissUse GmbH, Altis Biosystems Inc., Carcinotech Limited, Prellis Biologics Inc.

North America was the dominant region in the immuno-oncology co-culture models market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the immuno-oncology co-culture models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immuno-oncology co-culture models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.